Common 29 mtDNA Variant Panel

Test Information

This targeted panel includes 29 common known pathogenic mitochondrial DNA variants.

 

Turnaround Time

4 weeks

CPT Code(s)

81401x2, 81479

Cost

$1,400

Variants

  • m.1494C>T
  • m.1555A>G
  • m.1606G>A
  • m.3243A>G
  • m.3271T>C
  • m.3460G>A
  • m.4300A>G
  • m.8344A>G
  • m.8356T>C
  • m.8363G>A
  • m.8993T>C
  • m.8993T>G
  • m.9176T>C
  • m.9176T>G
  • m.9185T>C
  • m.10010T>C
  • m.10191T>C
  • m.10197G>A
  • m.11777C>A
  • m.11778G>A
  • m.12147G>A
  • m.12258C>A
  • m.12315G>A
  • m.13513G>A
  • m.13514A>G
  • m.14459G>A
  • m.14484T>C
  • m.14674T>C
  • m.14709T>C

Clinical Information

Mitochondrial disorders represent a clinically heterogeneous group of conditions caused by pathogenic variants in either nuclear or mitochondrial DNA. Some mitochondrial disorders affect a single organ while most involve multiple organ systems. Mitochondrial disorders may present at any age and often include prominent neurologic and myopathic features. Mitochondrial disorders have variable penetrance and severity of symptoms depending on the level of mutant mitochondria. or heteroplasmy, with a given individual or tissue type.

Indications

For patients with clinical suspicion of a mitochondrial disorder, molecular testing is useful to confirm the diagnosis and to identify the disease causing mutations within a family to allow for carrier testing. Individuals with Pearson syndrome or KSS and some patients with CPEO have large-scale (2-10 kb) mtDNA deletions, which will not be detected by the protocol used for this test.

Methodology

Next Generation Sequencing

Detection

Variants included in this panel account for >80% of MELAS, ~90% of MERRF, ~95% of LHON, ~ 50% of NARP, and ~ 20% of Leigh Syndrome cases. See Brochure for a breakdown of which variants account for what portion of each condition. Note: This test may not detect variants with a heteroplasmy of less than 10% using NGS. It is not possible to confirm all reported variants by Sanger sequencing because levels of mutant heteroplasmy 20% or lower may not be detected by Sanger. Additionally, levels of mutant heteroplasmy above 80% will appear homoplasmic by Sanger sequencing. Although this test is capable of collecting data on variants at other loci in the mitochondrial genome, it does not evaluate for variants other than those listed above. Additional variants which may be present in the patient are not reported with this test. Additionally, large deletions or duplications in the mitochondrial genome are not identified with the current sequencing protocol. As heteroplasmy levels vary from tissue to tissue, a negative blood test cannot completely rule out the chance that an individual carries a mtDNA variant that is either at very low heteroplasmy levels in the blood or present in a different tissue type.

Specimen Requirements

The required sample type is peripheral blood collected in an EDTA (purple top) tube - at least 2-3ml for pediatric patients and 5-6ml for adult patients. Maternal testing is performed free of charge. Maternal sample can be banked upfront to allow reanalysis if a variant is identified in the patient, or a maternal sample can be obtained after a variant has been identified in the proband, at which time an updated report will be issued for the patient.

Transport Instructions

The specimen should be kept at room temperature and delivered via overnight shipping. If shipment is delayed by one or two days, the specimen should be refrigerated and shipped at room temperature. Do not freeze the specimen. Samples collected on Friday can be safely designated for Monday delivery.

Have Questions? Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Falecia Thomas, MS, CGC

Meet Reggie Roper

Reggie has been part of the GGC family for over 18 years. He has short stature, webbing of his hands, pulmonary stenosis, seizures and hydrocephalus along with developmental delay. He carried an initial diagnosis of cardiofaciocutaneous (CFC) syndrome; however, as genetic testing advanced, GGC made the diagnosis of Noon...

In The News